On Monday, Kymera Therapeutics stock hit a key performance benchmark, with its Relative Strength (RS) Rating moving into the 90-plus percentile with an upgrade to 94, an increase from 88 the day before.
When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength. IBD's proprietary rating identifies price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the market's biggest winners tend to have an RS Rating north of 80 in the early stages of their moves.
See How IBD Helps You Make More Money In Stocks
Is Kymera Therapeutics Stock A Buy?
Kymera Therapeutics stock has been trading below its 200-day moving average and is not near a proper entry right now. See if it manages to form and break out from a proper base.
Although earnings and sales growth came in at -41% and -38%, respectively, in the latest report, that showed improvement for both the top and bottom lines.
Kymera Therapeutics stock holds the No. 224 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharma, Vertex Pharmaceuticals and Genmab are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
